Swedish drugmaker Sobi agreed to acquire Arthrosi Therapeutics for $950 million upfront, with up to $550 million in additional milestones, to add pozdeutinurad (AR882), a Phase III URAT1 inhibitor for progressive gout, to its pipeline. Sobi plans to fund the deal largely through debt and expects the acquisition to close in the first half of 2026. Arthrosi’s two Phase III studies are fully enrolled with readouts expected in Q2 2026; Sobi said the asset could materially accelerate growth and complement its existing gout portfolio. The deal underscores continued consolidation in specialty immunology and metabolic disease spaces and the strategic value placed on late‑stage oral small molecules.